This is a rare type of leukemia where the blood contains too many plasma cells. Plasma cells are a type of white blood cell that normally helps fight infection. In this condition, they grow uncontrollably and crowd out other healthy blood cells, making it hard for the body to fight infections and carry oxygen.
Every report comes from a Lived member, sent anonymously.
Have you tried Velcade (Bortezomib) for Plasma Cell Leukemia?
Plasma cell leukemia is a rare and aggressive form of multiple myeloma, a cancer of plasma cells. Plasma cells are white blood cells that normally make antibodies to fight infection. In myeloma, abnormal plasma cells multiply mainly inside the bone marrow. In plasma cell leukemia, large numbers of these cancerous cells also spill into the bloodstream and can spread to organs such as the liver and spleen. There are two forms. Primary plasma cell leukemia is present when the cancer is first found. Secondary plasma cell leukemia develops later in someone who already has myeloma, usually after the disease has advanced or stopped responding to treatment. Both behave more aggressively than typical myeloma and can worsen over weeks rather than months, which is why prompt diagnosis and treatment matter.
The cause of plasma cell leukemia is not known, and nothing a person did is known to bring it on. The cancerous cells often carry genetic changes that are linked to fast growth and harder-to-treat disease, but these changes develop within the cancer cells during a person's life rather than being inherited. Primary plasma cell leukemia tends to appear about 10 years earlier than typical myeloma, often around age 60. Like myeloma, it appears to be more common in Black Americans. Secondary plasma cell leukemia is being seen more often, probably because people with myeloma are living longer, which gives the disease more time to change into a leukemic form.
People often come to medical attention with symptoms of a very low red blood cell count (anemia), such as marked tiredness and breathlessness, along with bleeding or bruising from low platelets, kidney problems, or a high blood calcium level. Fewer people have the bone damage that is common in typical myeloma. The key test is a blood smear, in which a specialist looks at a blood sample under the microscope and counts the plasma cells among the white blood cells. Since 2021, the International Myeloma Working Group has defined primary plasma cell leukemia as 5% or more plasma cells in the blood of someone who otherwise meets the criteria for active multiple myeloma. Older definitions required 20% or more, so people diagnosed under the newer standard may have a somewhat lower count. Because plasma cells can briefly appear in the blood during severe infections or some other illnesses, a test called flow cytometry is used to confirm that the circulating cells are all copies of one cancerous cell. A bone marrow biopsy, blood and urine tests for the abnormal antibody protein, genetic tests on the cancer cells, and often a whole-body imaging scan that highlights active cancer outside the bone marrow help show how widespread the disease is and how it is likely to behave.
Treatment usually begins as soon as possible after diagnosis, because the disease can progress quickly. The first goal is to bring the cancer under control fast. Current approaches borrow from treatment for high-risk myeloma and combine several drugs at once, often four. These typically include a proteasome inhibitor such as bortezomib (Velcade), which blocks the machinery myeloma cells depend on to clear damaged proteins, along with an immune-modulating drug such as lenalidomide (Revlimid), a steroid, and often an antibody that targets myeloma cells. The care team also monitors blood chemistry and kidney function closely at the start, since many cancer cells breaking down at once can strain the kidneys. For people fit enough, initial therapy is usually followed by high-dose chemotherapy and an autologous stem cell transplant, which uses the person's own previously collected blood stem cells to restore the bone marrow. A transplant from a donor (allogeneic transplant) is considered for a small number of younger people, but it carries higher treatment-related risks and its benefit in this disease is uncertain. After transplant or initial therapy, ongoing consolidation and maintenance treatment aim to keep the disease from returning. Newer immune therapies developed for myeloma have shown promise. These include chimeric antigen receptor (CAR-T) cell therapy, in which a person's own immune cells are engineered in a laboratory to attack myeloma cells, and bispecific antibodies, which link immune cells directly to myeloma cells. They have been used mainly when the disease returns. Because plasma cell leukemia is rare and people with it were often excluded from major myeloma studies, much of the evidence comes from small studies and expert experience. Clinical trials are an important option to ask about at diagnosis and at relapse.
Plasma cell leukemia is a serious diagnosis with a poorer outlook than typical myeloma. Many people with primary plasma cell leukemia respond quickly to initial treatment, sometimes deeply, but the disease tends to come back sooner than ordinary myeloma, which is why maintenance treatment continues after the first phase. Secondary plasma cell leukemia is usually harder to treat because the cancer has already become resistant to earlier therapies. Outcomes have improved with modern drug combinations and transplant, but published survival figures come from small or older studies and cannot predict how one person will do. The first months are often intensive, with frequent clinic visits, blood tests, possible hospital stays, and preparation for transplant if it is planned. Infections are a particular concern because both the disease and its treatment weaken the immune system. Later, maintenance therapy and regular blood and urine tests track whether the disease is staying under control, so that a relapse can be treated early. Care at a center experienced in myeloma, support for fatigue and daily tasks, and early conversations about goals and priorities can help people and their families manage the demands of treatment.
Someone with myeloma should contact their care team promptly about new or worsening tiredness, unusual bleeding or bruising, or other changes in how they feel, since these can be early signs that the disease is changing. Without a diagnosis, these symptoms together, especially with weight loss or frequent infections, warrant a medical evaluation soon rather than at a routine visit. During treatment, call the care team right away for a fever of 100.5°F (38°C) or higher, chills, or other signs of infection, because infections in people receiving cancer treatment can become life threatening and need urgent medical attention.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Plasma Cell Leukemia is like, what's helped you, or ask the community a question.